Elyse C. Page

Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia.

The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia.

Journal: Neoplasia (New York, N.Y.)
Published: April 21, 2026

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Journal: HemaSphere
Published: March 18, 2026

The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemia.

The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemia.

Journal: Gut pathogens
Published: February 24, 2026

Case Report: Identification of rare H3-3A p.G35W variant in a case of adolescent tectal plate low-grade glioma.

Case Report: Identification of rare H3-3A p.G35W variant in a case of adolescent tectal plate low-grade glioma.

Journal: Frontiers in oncology
Published: December 21, 2025

Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.

Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.

Journal: Leukemia
Published: December 17, 2025

Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.

Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.

Journal: EJHaem
Published: October 30, 2025

High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib.

High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib.

Journal: Pediatric blood & cancer
Published: August 28, 2025

Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" study.

Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" study.

Journal: HemaSphere
Published: July 23, 2025

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain.

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain.

Journal: Blood neoplasia
Published: November 21, 2024

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.

Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.

Journal: Blood
Published: March 25, 2024

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol.

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol.

Journal: Blood neoplasia
Published: March 06, 2024

Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients.

Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia Patients.

Journal: Cancers
Published: September 15, 2023
Showing 1-12 of 20

Last Updated: 09/26/2026